Suppr超能文献

发育障碍成年患者中阿立哌唑介导的潜在锥体外系症状。

Potential aripiprazole-mediated extrapyramidal symptoms in an adult with developmental disabilities.

作者信息

Brahm Nancy C, McElwain David L, Brown Robert C

机构信息

Department of Pharmacy: Clinical and Administrative Sciences, College of Pharmacy, University of Oklahoma (UO), Tulsa 74135-2512, USA.

出版信息

Am J Health Syst Pharm. 2007 Apr 15;64(8):827-9. doi: 10.2146/ajhp060209.

Abstract

PURPOSE

A case of extrapyramidal symptoms (EPS) following administration of aripiprazole to a man with developmental disabilities who had never received antipsychotic medications and had no history of movement disorders is presented.

SUMMARY

The patient was a 40-year-old male with developmental disabilities. He was nonverbal, profoundly mentally retarded, and diagnosed with obsessive compulsive disorder (OCD) and orthopedic problems. He developed episodic movements possibly consistent with EPS secondary to aripiprazole usage. The patient was antipsychotic naive before initiation of aripiprazole 5 mg daily. Concurrent medications at the time of EPS onset included oxazepam, baclofen, and citalopram. Baclofen and oxazepam were prescribed secondary to right-sided hemiparesis contractures. Aripiprazole, 5 mg daily, was initiated in November 2004 as an augmentation strategy for the diagnosis of OCD. Facial, tongue, and arm movements were first reported approximately five weeks after the initiation of aripiprazole. Initial symptoms resolved after approximately 24 hours. The dosage was increased to 10 mg daily two weeks later. Dystonic episodes continued on an intermittent basis, and the patient presented with lower-lip thrusting and upper-limb athetosis. These movements interfered with the patient's eating, chewing, and holding of utensils. Several of the standard treatment strategies for EPS were used. Initially, diphenhydramine hydrochloride 25 mg was administered orally every six hours. The patient's movements resolved following diphenhydramine administration. Aripiprazole was subsequently discontinued secondary to its lack of efficacy for OCD and the development of a movement disorder.

CONCLUSION

A patient with developmental disabilities who had no history of movement disorders developed EPS following initiation of aripiprazole.

摘要

目的

本文报告一例从未接受过抗精神病药物治疗且无运动障碍病史的发育障碍男性在服用阿立哌唑后出现锥体外系症状(EPS)的病例。

摘要

该患者为一名40岁的发育障碍男性。他无法言语,智力严重低下,被诊断患有强迫症(OCD)和骨科问题。他出现了间歇性运动,可能与使用阿立哌唑继发的EPS相符。在开始每日服用5毫克阿立哌唑之前,该患者未曾使用过抗精神病药物。EPS发作时的同时服用药物包括奥沙西泮、巴氯芬和西酞普兰。巴氯芬和奥沙西泮是因右侧偏瘫挛缩而开具的。2004年11月开始每日服用5毫克阿立哌唑,作为强迫症诊断的强化治疗策略。在开始服用阿立哌唑约五周后首次报告面部、舌头和手臂运动。最初的症状在约24小时后缓解。两周后剂量增加至每日10毫克。肌张力障碍发作持续间歇性出现,患者出现下唇前突和上肢手足徐动症。这些运动干扰了患者的进食、咀嚼和握持餐具。使用了几种EPS的标准治疗策略。最初,每六小时口服25毫克盐酸苯海拉明。服用苯海拉明后患者的运动症状缓解。随后因阿立哌唑对OCD缺乏疗效且出现运动障碍而停药。

结论

一名无运动障碍病史的发育障碍患者在开始服用阿立哌唑后出现了EPS。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验